ArticleBMC infectious diseases2026
Genome characterization of the SARS-CoV-2 omicron in Cameroon.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe omicron lineage has been declared the fifth variant of concern (VOC) by the World Health Organization (WHO). This study aims to describe the genomic characteristics of omicron sequences from Cameroon and to discuss the potential implications of identified mutations for viral evolution and immune escape, based on existing literature.
methodsThis study is a retrospective analysis of publicly available SARS-CoV-2 sequences from Cameroon submitted to GISAID (Global Initiative on Sharing Avian Influenza Data). Full-length omicron sequences from across Cameroon were retrieved from the GISAID database. Phylogenetic analyses were conducted using Nextstrain SARS-CoV-2 Workflow version 8.2.0, and mutation analysis was performed using the Nextstrain web tool, with the Wuhan-Hu-1/2019 strain as a reference.
resultsA total of 1,428 omicron sequences were analyzed, revealing eleven variants: BA.1 lineage (45.0%), B.1.1.529 (0.2%), BA.2 (7.7%), BA.4 (6.5%), BA.5 (16.3%), BE (12.2%), BF (6.3%), BN.2 (0.1%), BQ.1 (3.7%), XBB (0.5%) and JN.1 (1.5%). The sequences exhibited high number of mutations in the spike gene, with the JN.1 lineage showing the highest mutation count. All lineages contained mutations associated with neutralizing antibody evasion, including R346T, K417N, G446S, E484A, or Q493R.
conclusionsOngoing monitoring of omicron lineages is crucial to detect emerging variants and adapt vaccine strategies. The significant mutations, particularly in the JN.1 lineage warrant further investigation to assess their potential impact on transmissibility or immune escape. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.